Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies
Phase 1
Withdrawn
- Conditions
- Malignant Neoplasms of Digestive OrgansMalignant Neoplasms of Female Genital OrgansMalignant Neoplasms of Lip Oral Cavity and PharynxMalignant Neoplasms of Male Genital Organs
- Interventions
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02812056
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT02807883
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
Phase 1
Completed
- Conditions
- Blood And Marrow TransplantationAdult Respiratory Distress Syndrome
- Interventions
- Biological: Mesenchymal Stem Cells (MSCs)
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT02804945
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02801578
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases
Phase 2
Completed
- Conditions
- Metastatic Malignant Neoplasm in the Brain
- Interventions
- Radiation: Frameless Fractionated Stereotactic Radiation Therapy
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT02798029
- Locations
- 🇺🇸
Presbyterian Hospital, Albuquerque, New Mexico, United States
🇺🇸MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
Early Phase 1
Active, not recruiting
- Conditions
- DysplasiaLip and Oral Cavity CarcinomaOral DisorderPremalignant Lesion
- Interventions
- Procedure: BiopsyProcedure: Fluorescence ImagingProcedure: High-Resolution Microendoscopy
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT02790853
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
Phase 2
Completed
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02784496
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML)Chronic Phase Phase Chronic Myelogenous Leukemia (CML)Blast Phase Chronic Myelogenous Leukemia (CML)Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
- Interventions
- First Posted Date
- 2016-05-25
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02782403
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
Not Applicable
Active, not recruiting
- Conditions
- Malignant Neoplasms of Female Genital Organs
- Interventions
- Device: AccelerometerBehavioral: QuestionnairesBehavioral: Fitness TestBehavioral: Resistance TrainingBehavioral: Aerobic ExerciseBehavioral: Telephone Coaching/Phone CallsBehavioral: Video Chat Sessions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT02774759
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
Not Applicable
Active, not recruiting
- Conditions
- Deleterious BARD1 Gene MutationDeleterious MSH2 Gene MutationDeleterious RAD51D Gene MutationDeleterious BRCA2 Gene MutationDeleterious MLH1 Gene MutationPremenopausalDeleterious BRCA1 Gene MutationDeleterious BRIP1 Gene MutationDeleterious EPCAM Gene MutationDeleterious MSH6 Gene Mutation
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentProcedure: OophorectomyProcedure: Salpingo-OophorectomyProcedure: Salpingectomy
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 374
- Registration Number
- NCT02760849
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath